Lisdexamfetamine dimesylate (CAS: 608137-33-3) is a prodrug of the central nervous system (CNS) stimulant dextroamphetamine. It is used for the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). Lisdexamfetamine dimesylate was first approved by the US Food and Drug Administration (FDA) in 2007 under the brand name Vyvanse. This article will provide an overview of lisdexamfetamine dimesylate, including its chemical properties, health benefits, potential effects, product mechanism, safety, side effects, dosing information, and a conclusion on its use.
Chemical Properties The chemical name for lisdexamfetamine dimesylate is L-lysine N-(1-oxido-2-amino-5-methylhexane)amide dimethanesulfonate. Its molecular formula is C15H25N3O•(CH4O3S)2, and it has a formula weight of 455.55 g/mol. The CAS number for this compound is 608137-33-3.
Top Ten Keywords/Synonyms
Health Benefits Lisdexamfetamine dimesylate is primarily used for the treatment of ADHD and binge eating disorder. It works by increasing the levels of dopamine and norepinephrine in the brain, which are neurotransmitters that play a key role in regulating attention, impulse control, and appetite. By increasing the levels of these neurotransmitters, lisdexamfetamine dimesylate can help improve symptoms of ADHD and reduce episodes of binge eating.
Potential Effects In clinical trials, lisdexamfetamine dimesylate has been shown to be highly effective at improving symptoms of ADHD and reducing episodes of binge eating in patients with BED. It has also been found to be well-tolerated, with few serious side effects reported. Additionally, lisdexamfetamine dimesylate has demonstrated good pharmacokinetic properties, meaning it is well-absorbed and distributed throughout the body, and is metabolized and eliminated from the body in a predictable manner.
Product Mechanism Lisdexamfetamine dimesylate is a prodrug of dextroamphetamine, which means that it is converted into dextroamphetamine in the body. Dextroamphetamine is a CNS stimulant that increases the release of dopamine and norepinephrine from nerve endings in the brain, thereby improving attention, focus, and impulse control.
Safety Overall, lisdexamfetamine dimesylate has been found to be safe and well-tolerated in clinical trials. However, like all medications, it does carry some risks of side effects and adverse events. Patients taking lisdexamfetamine dimesylate should be monitored regularly for any signs of cardiac dysfunction, psychiatric symptoms, or other serious side effects.
Side Effects Some of the most common side effects reported with lisdexamfetamine dimesylate include dry mouth, insomnia, irritability, and decreased appetite. These side effects are usually mild to moderate in severity and go away on their own over time. More serious side effects, such as cardiovascular events or psychotic symptoms, are rare but can occur in some patients.
Dosing Information Lisdexamfetamine dimesylate is typically taken orally, either with or without food. The recommended dose for patients with ADHD is 30 mg once daily in the morning. For patients with BED, the starting dose is 30 mg once daily in the morning, with the option to increase the dose by 20 mg per week up to a maximum of 70 mg/day. Patients should follow their healthcare provider's instructions carefully when taking this medication.
Conclusion Lisdexamfetamine dimesylate is a highly effective and well-tolerated medication used for the treatment of ADHD and binge eating disorder. As a prodrug of dextroamphetamine, it increases the levels of dopamine and norepinephrine in the brain, thereby improving attention, focus, and impulse control. While it does carry some risks of side effects and adverse events, overall, it has been found to be safe and effective in clinical trials. Patients taking lisdexamfetamine dimesylate should work closely with their healthcare providers to ensure proper dosing and monitoring for any potential side effects
